DYN · Dyne Therapeutics, Inc.
$26.51
+0.53 (+2.04%)
At close · Aug 21
Market Cap
$4.85B
Shares
186.75M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Erick Lucera | Chief Financial Officer | $2,695,986 |
| John G. Cox | President and Chief Executive Officer | $2,076,868 |
| Johanna Friedl-Naderer | Chief Commercial Officer | $1,086,420 |
| Douglas Kerr | Chief Medical Officer | $1,057,598 |
| Oxana Beskrovnaya | Chief Innovation Officer; Former Chief Scientific Officer | $992,628 |
| Richard Scalzo | Former Senior Vice President, Head of Finance and Administration | $727,638 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| John G. Cox | President and Chief Executive Officer | $20,688,724 |
| Josh Brumm | Former President and Chief Executive Officer | $14,383,011 |
| Johanna Friedl-Naderer | Chief Commercial Officer | $8,190,480 |
| Douglas Kerr | Chief Medical Officer | $7,741,647 |
| Oxana Beskrovnaya | Chief Scientific Officer | $3,835,650 |
| Richard Scalzo | Former Senior Vice President, Head of Finance and Administration | $2,485,672 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Josh Brumm | Former President and Chief Executive Officer | $5,974,491 |
| Jonathan McNeill | Chief Business Officer | $2,230,830 |
| Susanna High | Chief Operating Officer | $2,045,442 |
| Oxana Beskrovnaya | Chief Scientific Officer | $1,997,845 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joshua Brumm | President and Chief Executive Officer | $4,317,103 |
| Josh Brumm | Former President and Chief Executive Officer | $4,317,103 |
| Susanna High | Chief Operating Officer | $1,594,292 |
| Oxana Beskrovnaya | Chief Scientific Officer | $1,486,373 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joshua Brumm | President and Chief Executive Officer | $4,086,611 |
| Oxana Beskrovnaya | Chief Scientific Officer | $2,908,952 |
| Susanna High | Chief Operating Officer | $1,690,621 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Joshua Brumm | President and Chief Executive Officer | $11,868,105 |
| Romesh Subramanian | Chief Scientific Officer | $4,370,975 |
| Susanna High | Chief Operating Officer | $3,745,915 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Romesh Subramanian | Chief Scientific Officer | $411,660 |
| Joshua Brumm | President and Chief Executive Officer | $277,314 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Barry E. Greene | Class I director | Appointed | 2026-06-22 |
| Vikram Karnani | Class II director | Appointed | 2025-12-23 |
| Brian Posner | Class III director | Appointed | 2025-10-02 |
| Erick Lucera | principal accounting officer | Appointed | 2025-03-20 |
| Erick Lucera | Chief Financial Officer and Treasurer | Appointed | 2025-03-20 |
| Johanna Friedl-Naderer | chief commercial officer | Appointed | 2024-09-03 |
| Lucia Celona | chief human resources officer | Appointed | 2024-09-03 |
| Wildon Farwell | chief medical officer | Resigned | 2024-09-03 |
| Doug Kerr | chief medical officer | Appointed | 2024-09-03 |
| Susanna High | Chief Operating Officer | Resigned | 2024-09-03 |
| Jonathan McNeill, M.D. | Chief Business Officer | Resigned | 2024-09-03 |
| John Cox | Class I director | Appointed | 2024-03-25 |
| John Cox | President and Chief Executive Officer | Appointed | 2024-03-25 |
| Dr. Lawrence Klein | member of the Board of Directors | Resigned | 2023-05-25 |
| Carlo Incerti, M.D. | Class I director | Appointed | 2022-03-03 |
| Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | Appointed | 2021-06-02 |
| Romesh Subramanian, Ph.D. | Chief Scientific Officer | Resigned | 2021-06-02 |
Key facts
CIK
1818794
CUSIP
26818M108
13F (30d)
237 filings
231 filers
Visit website
Investor relations